The cure rate, survival rate, and treatable cancer type of baryon cancer treatment effect

중입자암치료 효과

Comparison of local treatment rates of baryon cancer treatment and radiation therapy (on a 3-year basis)

Head and neck cancer local control rate 78% particle / 70% radiation

Local control rate of lung cancer 95% / 30%

Local control rate of liver cancer 90% / 50%

Pancreatic cancer local control rate 95% / 30%

100% prostate cancer / 80%

Custard cancer 80% 30%



Clinical statistics for baryon cancer treatment

NIRS (1994/06~2013/02)

 

Protocols NIRS (1994~2013)	Number of patients	Local control rate	survival rate
	7077	3 years	3 years	5 years
Head/head/bottom average	809	85.1%	67.3%	56.3%
lung cancer average	679	88%	61.4%	41.8%
liver cancer average	284	88.8%	60.8%	38%
prostate mean	3869	99%	96%	93.7%
uterine cancer average	35	58.7%	51.7%	45%
Bone soft cancer mean	999	77.6%	70%	51.8%
rectal cancer	229	90%	67%	45%
Pancreatic Cancer Average	139	62.5%	42.7%	37.4% *2 years
esophageal cancer mean	34	-	92%	78%  *2years

중입자 암치료 가능한 환부

Targeted carcinoma	Applicable (pathology/weapons)
a brain tumor	glioblastoma
head and neck cancer	cystic carcinoma, mucosal melanoma, sarcoma, salivary gland cancer, sinus tumor, tear gland, ear tumor
cancer of the esophagus	Local Progressive (Stage I-III)
lung cancer	Weapons I, II, Weapons III (partial)
cancer of the liver	Local lesions (hepatic cell cancer, intrahepatic biliary tract cancer)
pancreatic cancer	a local progressive form
gynecological cancer	"Cervical cervical cancer (flat epithelial cell cancer, adenocarcinoma), uterine cancer (non-surgical, local progressive),
prostate cancer	"Blackoma"
rectal cancer	Local lesion (low-risk group to high-risk group)
breeding	recurrent cancer/inoperable lesion
Besides that,	Chordoma, cartilage sarcoma, inoperable soft/bone sarcoma

 

[Patient who can treat heavy particles]

a patient diagnosed with cancer by a medical institution

Cancer patients in stage 1 to stage 2 (There are also possible stages 3 to 4)

Patients without metastasis (some local metastasis is possible)

Lesions within 15 cm in diameter
Patients who have no history of radiation therapy at the target site within at least one year

Visually assessable single-stage solid cancer

 multiple tumors clustered in one place

*Can be treated according to the doctor's diagnosis other than the above

---

Inquiries about medical treatment and establishment of overseas branches

[IAEC headquarters]

VIP Counseling Center: 181F, Yangjaecheon-ro 11-gil, Seocho-gu, Seoul

Representative number: +82-2-1566-2329

Homepage: www.iaecms.com

Email: cs@iaecms.com

Kakao Talk Channel: @IAEC



IAEC is the direct management center of Japan Heavy Industries Hospital

It's the only company that can officially attract.



Foreign patient attraction business registration number A202201014591
Tourism business registration number 2022000043
Foreign Patient Guarantee Insurance 100 million won
Travel guarantee insurance 50 million won


[Introduction of the company]

IAEC has seven overseas branches in Japan, South Korea, Seattle, the Philippines, Vietnam, Taiwan and Singapore

It is a medical concierge service company that provides advanced medical care to more than 10,000 patients each year in connection with major hospitals around the world

IAEC is a subsidiary of AEC, the world's only and first heavy particle accelerator operating company founded in 1992, and currently specializes in cancer treatment and is expanding its services to various medical fields

AEC is currently operating five centers for treating baryon cancer in Japan and is also working with Korea's Yonsei Severance baryon center and Seoul National University Hospital.

It is the only company in the world that is directly linked to a heavy particle center and has permission to attract overseas patients and traveler's insurance.